TrialLancet (London, England)2021

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Paul Baas et al.PubMed ↗Publisher ↗

No numbers read from the abstract.